Zevra Therapeutics (ZVRA) Receivables - Other (2018 - 2024)
Zevra Therapeutics (ZVRA) has disclosed Receivables - Other for 7 consecutive years, with $333000.0 as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Receivables - Other fell 73.53% year-over-year to $333000.0, compared with a TTM value of $333000.0 through Dec 2024, down 73.53%, and an annual FY2024 reading of $333000.0, down 73.53% over the prior year.
- Receivables - Other was $333000.0 for Q4 2024 at Zevra Therapeutics, down from $1.3 million in the prior quarter.
- Across five years, Receivables - Other topped out at $1.3 million in Q4 2023 and bottomed at $107000.0 in Q4 2021.
- Average Receivables - Other over 5 years is $504454.5, with a median of $400000.0 recorded in 2021.
- The sharpest move saw Receivables - Other surged 941.12% in 2022, then crashed 73.53% in 2024.
- Year by year, Receivables - Other stood at $137000.0 in 2020, then decreased by 21.9% to $107000.0 in 2021, then soared by 941.12% to $1.1 million in 2022, then grew by 12.93% to $1.3 million in 2023, then plummeted by 73.53% to $333000.0 in 2024.
- Business Quant data shows Receivables - Other for ZVRA at $333000.0 in Q4 2024, $1.3 million in Q4 2023, and $700000.0 in Q1 2023.